1. Home
  2. IVVD vs NYXH Comparison

IVVD vs NYXH Comparison

Compare IVVD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$0.61

Market Cap

201.9M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.51

Market Cap

161.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVVD
NYXH
Founded
2020
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.9M
161.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
IVVD
NYXH
Price
$0.61
$1.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$8.75
$9.33
AVG Volume (30 Days)
5.2M
217.1K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
79.02
N/A
EPS
N/A
N/A
Revenue
$53,426,000.00
N/A
Revenue This Year
$61.57
$213.98
Revenue Next Year
$41.42
$126.25
P/E Ratio
N/A
N/A
Revenue Growth
110.47
N/A
52 Week Low
$0.49
$1.26
52 Week High
$3.07
$8.59

Technical Indicators

Market Signals
Indicator
IVVD
NYXH
Relative Strength Index (RSI) 28.31 32.98
Support Level N/A $1.26
Resistance Level $1.01 $1.70
Average True Range (ATR) 0.08 0.10
MACD -0.01 0.02
Stochastic Oscillator 1.97 2.78

Price Performance

Historical Comparison
IVVD
NYXH

About IVVD Invivyd Inc.

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: